IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, announced that a number of industry leaders discussed the successes achieved by their patients in a variety of body sites being treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer seeds at the “Advances in Brachytherapy” symposium, held at Weill Cornell on Friday and Saturday.
IsoRay Chairman and CEO Dwight Babcock commented, “We are so very pleased to have studies presented reporting successes in peer to peer presentations. Data from ongoing studies continues to be gathered and when it matures the expectation is that it will be peer reviewed and published. We are now hearing from more institutions based on our new recently released peer reviewed publications. Medical professionals rely on these publications to further their practice and learn about new leading edge products.”
NOTES FROM THE FIELD AT THE SYMPOSIUM
1.) LDR Brachytherapy: MD Anderson Experience – Steve Frank, M.D.
Dr. Frank discussed the ongoing prostate cancer trial at MD Anderson Cancer Center in Houston, including the use of Cesium-131 as treatment. He also discussed the emerging use of magnetic resonance (MR) imaging in determining radiation doses delivered following prostate brachytherapy. Cesium-131 was the first isotope chosen to be used in conjunction with the MRI spacer.
2.) Role of Brachytherapy in Recurrent H&N Cancers – Bhupesh Parashar, M.D.
Dr. Parashar discussed the option of Cesium-131 brachytherapy as part of the management of recurrent head and neck cancers. Details on this study were recently presented at the 97th Annual Meeting of the American Radium Society.
3.) Resection with intraoperative Cs-131 Brachytherapy in Newly Diagnosed Brain Metastases and Recurrent GBM: Techniques and Outcomes – Theodore Schwartz, M.D. and A. Gabriella Wernicke, M.D.
Drs. Schwartz and Wernicke described their study, published recently in the Journal of Neurosurgery, where very high rates of control have been seen in the treatment of metastatic brain cancer. In particular they noted the benefit of cesium-131 treatment in tandem with surgery over waiting weeks or months to perform other types of radiation treatment. Their group continues to add patients to their existing study and they are planning a trial to compare cesium-131 treatment to other radiation treatments in the treatment of brain metastases.
4.) Impact of Brachytherapy on Local Recurrence Rates after Sublobar Resection in Early Stage Non-Small Cell Lung Cancer – Bhupesh Parashar, M.D.
Dr. Parashar discussed the role of cesium-131 brachytherapy in addition to lung sparing wedge resection surgery for patients with operable lung cancers. Although there is some discussion ongoing regarding the use of brachytherapy in these cases, Dr. Parashar stated that he continues to see the value of cesium-131 brachytherapy for appropriately selected patients.
IsoRay Chairman and CEO Dwight Babcock noted, “Cesium-131 continues to impress medical professionals as reported successes are showing positive results in treating some of the toughest cancer cases. Many of our cases are brought by physicians seeking solutions where first line treatments have failed. Following Cesium-131 treatment, patients are having better outcomes with improved quality of life. Therapy with Cs-131 is successfully treating patients who failed conventional therapies and we believe that it could help many other patients. We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite®radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life. (Original Source)
Shares of IsoRay Inc opened today at $1.78 and are currently trading down at $1.7106. ISR has a 1-year high of $3.29 and a 1-year low of $1.22. The stock’s 50-day moving average is $1.58 and its 200-day moving average is $1.55.
On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR, with a price target of $5, in a report issued on February 18. The current price target represents a potential upside of 180.9% from where the stock is currently trading.
According to TipRanks.com, Kolbert has a total average return of 0.5%, a 40.4% success rate, and is ranked #2049 out of 3596 analysts.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.